ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH GRÜNENTHAL FOR MIGRAINE TREATMENT ZOMIG
3 July 2017 07:00 BST AstraZeneca announced today that it has completed the previously-announced agreement with Grünenthal for the global rights to Zomig (zolmitriptan) outside Japan. Zomig is indicated for the acute treatment of migraines and cluster headaches, an area of medicine outside AstraZeneca's strategic focus. The net consideration from the upfront payment received from Grünenthal will be